<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ranibizumab (including biosimilars): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ranibizumab (including biosimilars): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ranibizumab (including biosimilars): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12053" href="/d/html/12053.html" rel="external">see "Ranibizumab (including biosimilars): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="127393" href="/d/html/127393.html" rel="external">see "Ranibizumab (including biosimilars): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F56455074"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Endophthalmitis (implant):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosion may reduce the risk of endophthalmitis. In clinical trials, 2% of patients receiving an implant experienced at least 1 episode of endophthalmitis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3025066"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Byooviz;</li>
<li>Cimerli;</li>
<li>Lucentis;</li>
<li>Susvimo (Implant 1st Fill);</li>
<li>Susvimo (Implant Refill)</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868801"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Byooviz;</li>
<li>Lucentis</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3025070"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiogenesis Inhibitor;</li>
<li>
                        Monoclonal Antibody;</li>
<li>
                        Ophthalmic Agent;</li>
<li>
                        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F3025114"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In the United States, Byooviz (ranibizumab-nuna) and Cimerli (ranibizumab-eqrn) are approved as biosimilars to Lucentis (ranibizumab). In Canada, Byooviz is approved as a biosimilar to Lucentis; refer to the Canadian product monograph for biosimilar-specific labeled indications. Initial and follow-up visits to assess clinical outcomes should occur every ~4 weeks with an experienced ophthalmology team (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757502'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="00dc0d3a-8e07-431d-8cf1-8d2a58a1c1bc">Age-related macular degeneration, neovascular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Age-related macular degeneration, neovascular (wet):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Lucentis and ranibizumab biosimilars: <b>Intravitreal (injection):</b> 0.5 mg once a month (approximately every 28 days). After 3 or 4 consecutive monthly doses, dosing interval may be extended (eg, once every 3 months or once monthly as needed based on response) with regular assessment (ie, "treat and extend" strategy); "treat and extend" strategies should only be done under the supervision of an experienced ophthalmology team (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757502','lexi-content-ref-19376495','lexi-content-ref-31687203','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757502','lexi-content-ref-19376495','lexi-content-ref-31687203','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> A regimen averaging 4 to 5 doses over 9 months is expected to maintain visual acuity and an every-3-month dosing regimen has reportedly resulted in a ~5 letter (1 line) loss of visual acuity over 9 months, as compared to monthly dosing which may result in an additional ~1 to 2 letter gain.</p>
<p style="text-indent:-2em;margin-left:4em;">Susvimo: <b>Intravitreal (implant):</b> 2 mg (0.02 mL of <b>100 mg/mL</b> solution) delivered continuously with refills administered every 24 weeks (approximately every 6 months). Supplemental intravitreal injections (Lucentis) of 0.5 mg (0.05 mL of <b>10 mg/mL</b> solution) may be administered to the affected eye while implant is in place, if needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed refill exchange:</i> Administer as soon as possible and perform subsequent refills 24 weeks (~6 months) thereafter.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="867af98d-205e-460e-8955-a72b16570934">Diabetic macular edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema:</b> Lucentis and Cimerli only:<b> Intravitreal (injection):</b> 0.3 mg once a month (approximately every 28 days); in clinical trials, monthly doses of 0.5 mg were also studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20980427','lexi-content-ref-21459215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20980427','lexi-content-ref-21459215'])">Ref</a></span>). After 3 consecutive monthly doses (if using the 0.5 mg dose), dosing interval may be extended (eg, by 2 to 4 weeks) based on response with regular assessment (ie, "treat and extend" strategy); "treat and extend" strategies should only be done under the supervision of an experienced ophthalmology team (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757502','lexi-content-ref-32887464','lexi-content-ref-34012972','lexi-content-ref-32492069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757502','lexi-content-ref-32887464','lexi-content-ref-34012972','lexi-content-ref-32492069'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cfae73ee-ae0e-49db-bb03-1d2db5de1cec">Diabetic retinopathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic retinopathy:</b> Lucentis and Cimerli only: <b>Intravitreal (injection):</b> 0.3 mg once a month (approximately every 28 days).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="536daf52-bb29-4d68-ada8-113232d4acb3">Macular edema following retinal vein occlusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular edema following retinal vein occlusion:</b> Lucentis and ranibizumab biosimilars: <b>Intravitreal (injection):</b> 0.5 mg once a month (approximately every 28 days). After 3 consecutive monthly doses, dosing interval may be extended based on response with regular assessment (ie, "treat and extend" strategy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32555630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32555630'])">Ref</a></span>). "Treat and extend" strategies should only be done under the supervision of an experienced ophthalmology team (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31757502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31757502'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f29b2e1c-809b-4c52-ae93-32472025ef05">Myopic choroidal neovascularization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myopic choroidal neovascularization:</b> Lucentis and ranibizumab biosimilars: <b>Intravitreal (injection):</b> 0.5 mg once a month (approximately every 28 days) for up to 3 months; may retreat if necessary.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991989"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989225"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, significant systemic exposure is not expected.</p></div>
<div class="block dot drugH1Div" id="F56459772"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Implant (Susvimo): Refill-exchange modifications for adverse reactions:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intraocular inflammation ≥1 plus cells or flare, infectious endophthalmitis, local infections of either eye, severe systemic infection, or sight-threatening events (eg, rhegmatogenous retinal detachment, unexplained vision loss, vitreous hemorrhage):</i> Withhold refill-exchange.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Observed damage to the implant:</i> Withhold refill-exchange and consider implant removal.</p></div>
<div class="block doe drugH1Div" id="F3025115"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F3025079"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults receiving injection unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (1% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (implant: 12%; injection: 1% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (implant: 7%; injection: 3% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (3% to 12%), blurred vision (≤18%), cataract (2% to 28%), conjunctival hemorrhage (implant: 72%; injection: 47% to 74%), conjunctival hyperemia (implant: 26%; injection: 1% to 7%), dry eye syndrome (3% to 12%), eye irritation (7% to 15%), eye pain (implant: 10%; injection: 17% to 35%), eye pruritus (1% to 12%), foreign body sensation of eye (implant: 7%; injection: 7% to 16%), increased intraocular pressure (7% to 24%), increased lacrimation (2% to 14%), intraocular inflammation (1% to 18%), iritis (implant: 23%; including anterior chamber inflammation), maculopathy (5% to 11%), ocular hyperemia (5% to 11%), visual disturbance (≤18%), vitreous detachment (implant: 6%; injection: 4% to 21%), vitreous opacity (implant: 9%; injection: 7% to 27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (4% to 11%), nasopharyngitis (5% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (1% to 5%), peripheral edema (2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (3% to 8%), gastroesophageal reflux disease (1% to 6%), nausea (1% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Seasonal allergy (2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident (≤5%; including hemorrhagic stroke and ischemic stroke), peripheral neuropathy (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival abnormalities (conjunctival erosion or retraction; implant: ≤4%), conjunctival edema (implant: 5%), corneal abrasion (implant: 4%), corneal disease (implant: 4%), corneal edema (implant: 4%), encapsulated/cystic bleb (conjunctival; implant: ≤9%), endophthalmitis (implant: 2%), eye discomfort (2% to 7%), hypotony of eye (implant: 6%), inadvertent filtering bleb (conjunctival; implant: ≤9%), retinal degeneration (1% to 8%), retinopathy (2% to 10%), secondary cataract (2% to 7%), vitreous hemorrhage (implant: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Chronic renal failure (6%), renal failure syndrome (1% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Chronic obstructive pulmonary disease (1% to 6%), cough (1% to 9%), sinusitis (3% to 8%), upper respiratory tract infection (2% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (all formulations): Ophthalmic: Decreased visual acuity, rhegmatogenous retinal detachment</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all formulations): Ophthalmic: Retinal pigment epithelium tear</p></div>
<div class="block coi drugH1Div" id="F3025075"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to ranibizumab or any component of the formulation; ocular or periocular infection; active intraocular inflammation (implant only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Intravitreal injection: Active intraocular inflammation.</p></div>
<div class="block war drugH1Div" id="F3025076"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Conjunctival effects: Implant: Conjunctival bleb, erosion, and retraction have occurred and may lead to endophthalmitis; surgical intervention may be needed. Ensure appropriate intraoperative handling of the conjunctiva and Tenon’s capsule during implantation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endophthalmitis/retinal detachment: Intravitreous injections and implants may be associated with endophthalmitis and retinal detachments, resulting in vision loss. Proper aseptic injection techniques should be used. Areas of abnormal vitreo-retinal adhesion or retinal breaks should be treated prior to inserting the implant. Patients should be monitored for potential infection and report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately; early detection and prompt treatment should occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity may present as severe intraocular inflammation; instruct patients to report intraocular inflammation that increases with severity. Rare hypersensitivity reactions (including anaphylaxis) have been associated with another vascular endothelial growth factor (VEGF) inhibitor, pegaptanib, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure: Prior to and following intravitreal injection, intraocular pressure may increase. Onset is seen within 60 minutes postinjection. Monitor intraocular pressure before and after injection and manage accordingly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Septum dislodgement: Implant: Implant damage where the septum has dislodged into the implant body has been reported. Use appropriate handling (avoiding twisting and/or rotation) and insertion of the refill needle into the septum to minimize risk. Discontinue treatment if septum dislodgement occurs and consider implant removal if the benefits outweigh the risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Risk of thromboembolic events, particularly stroke, may be increased following intravitreal administration of VEGF inhibitors. Use caution in patients with known risk factors (eg, history of stroke, TIA).</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual acuity: Implant: A decrease in visual acuity on average of 4 letters in the first month and 2 letters in the second month was observed postoperatively following initial implantation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vitreous hemorrhage: Implant: Vitreous hemorrhages resulting in vision loss and requiring vitrectomy may occur. Most cases occurred within the first month postoperatively and many resolved spontaneously. Risk may be increased in patients on antithrombotic therapy; temporarily withhold antithrombotic medications prior to implantation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetic macular edema and diabetic retinopathy: Pooled analysis of trials involving patients with diabetic macular edema and diabetic retinopathy revealed a higher incidence of fatal events in patients treated with ranibizumab compared to control (3% in patients treated with 0.3 mg in the first 2 years compared to 1% in the control). Overall, the incidence of fatalities was consistent with deaths normally observed in patients with advanced diabetic complications; however, a potential association between fatal events and intravitreal administration of VEGF inhibitors cannot be excluded.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Implant: Appropriate use: For intravitreal use via surgical ocular implant only by a health care provider experienced in vitreoretinal surgery; do not administer as a bolus intravitreal injection. Minimize air bubbles within the implant reservoir. Do not use implant if air bubbles greater than one-third of the widest diameter of the implant are present during initial fill or excess air is present after initial fill; discard syringe and needle if excess air is present in the syringe and needle during refill-exchange procedure; if excess air is present after the refill-exchange, consider repeating procedure. If implant becomes dislocated, immediate surgical intervention is necessary; adhering to the scleral incision length and appropriate targeting of the pars plana during laser ablation may reduce the risk of dislocation. Use caution when performing ophthalmic procedures (eg, B-scan ophthalmic ultrasound, gonioscopy, scleral depression) that may cause deflection of the implant resulting in injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interchangeability: The implant vial is not interchangeable with other ranibizumab products.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• MRI: The implant is considered magnetic resonance conditional. Instruct patient to inform health care provider and show implant card prior to MRI.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54175178"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Systemic absorption with subsequent suppression of systemic vascular endothelial growth factor (VEGF) concentrations after intravitreal VEGF inhibitor administration has been reported (Hoerster 2013; Sato 2012; Wu 2017). Ranibizumab has been associated with less systemic VEGF suppression as compared to bevacizumab (Hoerster 2013; Wu 2017). Short- and long-term implications of systemic exposure are unknown; monitoring is recommended.</p>
<p style="text-indent:0em;margin-top:2em;">Ocular complications following intravitreal ranibizumab in preterm neonates with retinopathy of prematurity have been reported; complications described include cataract formation and endophthalmitis. Cataract formation was reported in a retrospective review and a randomized, open-label study (Chan 2016; Stahl 2019). In the retrospective review, 1 patient developed a cataract following injection 0.5 mm post-limbus; all other patients received injection 1 mm post-limbus with no additional cataract formation (Chan 2016). Endophthalmitis and an orbital infection developed 6 days after intravitreal ranibizumab in a patient who was treated for conjunctivitis and a staphylococcal periocular infection 11 days prior to ranibizumab with complete resolution; in addition the patient received prophylactic topical antibiotics 3 days immediately prior to ranibizumab; the authors concluded that preceding periocular infection should exclude neonates from receiving intravitreal ranibizumab (Stahl 2019).</p></div>
<div class="block foc drugH1Div" id="F3025123"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cimerli: Ranibizumab-eqrn 0.3 mg/0.05 mL (6 mg/mL) (0.05 mL); Ranibizumab-eqrn 0.5 mg/0.05 mL (10 mg/mL) (0.05 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Byooviz: Ranibizumab-nuna 0.5 mg/ 0.05 mL (0.05 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lucentis: 0.3 mg/0.05 mL (0.05 mL [DSC]); 0.5 mg/0.05 mL (0.05 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Susvimo (Implant 1st Fill): 10 mg/0.1 mL (0.1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Susvimo (Implant Refill): 10 mg/0.1 mL (0.1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravitreal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lucentis: 0.3 mg/0.05 mL (0.05 mL); 0.5 mg/0.05 mL (0.05 mL)</p></div>
<div class="block geq drugH1Div" id="F3025068"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322947"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Byooviz Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/0.05 mL (per 0.05 mL): $1,356.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cimerli Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/0.05 mL (per 0.05 mL): $979.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/0.05 mL (per 0.05 mL): $1,632.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Susvimo (Implant 1st Fill) Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG/0.1ML (per 0.1 mL): $9,600.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Susvimo (Implant Refill) Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG/0.1ML (per 0.1 mL): $9,600.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Lucentis Intravitreal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg/0.05 mL (per 0.05 mL): $1,404.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/0.05 mL (per 0.05 mL): $2,340.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868802"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Byooviz: 2.3 mg/0.23 mL (0.23 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lucentis: 2.3 mg/0.23 mL (0.23 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intravitreal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lucentis: 1.65 mg/0.165 mL (0.165 mL)</p></div>
<div class="block adm drugH1Div" id="F3025118"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intravitreal:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Implant (Susvimo): For intravitreal use via surgical ocular implant only by a health care provider experienced in vitreoretinal surgery; do not administer as a bolus intravitreal injection. Do not shake. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Implant should be filled aseptically with ranibizumab (over 5 to 10 seconds) immediately prior to insertion; no more than 30 minutes should pass between initial fill and surgical insertion. Refer to the complete instructions included in the insertion tool assembly carton for the initial fill, implant procedure, refill exchange, and proper removal. After insertion, instruct patient to keep head above shoulder for the rest of the day; sleep with head on 3 or more pillows during the day and the night after surgery; do not remove eye shield until instructed to do so by health care provider; wear eye shield at bedtime for at least 7 days following implant insertion; do not push on the eye, rub the eye, or touch the area of the eye where the implant is inserted for 30 days following surgery; and do not participate in strenuous activities until 1 month after implant insertion.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection (prefilled syringe [Lucentis], vial [Lucentis and ranibizumab biosimilars]): For ophthalmic intravitreal injection only. Each vial or prefilled syringe should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial or prefilled syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before ranibizumab is administered to the other eye. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Refer to manufacturer's labeling for additional detailed information.</p></div>
<div class="block admp drugH1Div" id="F54175203"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: For intravitreal injection only; injection of undiluted ranibizumab solution using a 30 gauge, <sup>1</sup>/<sub>2</sub>-inch needle should be performed by an experienced and qualified ophthalmologist (Huang 2017; Kang 2018; Wu 2017; Zhang 2017; Lucentis European Medicines Agency 2020). Ranibizumab prefilled syringes do not allow measurement of doses smaller than 0.3 mg and 0.5 mg and therefore should not be used for treatment of neonates. Use a new vial and supplies for treatment of second eye, if indicated. Topical anesthetics and topical antiseptics (eg, povidone-iodine, 5% Betadine) were administered to neonates undergoing retinopathy of prematurity treatment; some studies also administered topical antibiotics ranging from 1 dose to 7 days following ranibizumab injection (Chan 2016; Huang 2017; Kang 2018; Wu 2017; Zhang 2017).</p></div>
<div class="block use drugH1Div" id="F3030717"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic macular edema (Lucentis and Cimerli only):</b> Treatment of diabetic macular edema.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic retinopathy (Lucentis and Cimerli only):</b> Treatment of diabetic retinopathy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular degeneration:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Lucentis and ranibizumab biosimilars: Treatment of neovascular (wet) age-related macular degeneration (AMD).</p>
<p style="text-indent:-2em;margin-left:4em;">Susvimo: Treatment of neovascular (wet) AMD in patients who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor inhibitor medication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular edema (Lucentis and ranibizumab biosimilars):</b> Treatment of macular edema following retinal vein occlusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myopic choroidal neovascularization (Lucentis and ranibizumab biosimilars):</b> Treatment of myopic choroidal neovascularization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In the United States, Byooviz (ranibizumab-nuna) and Cimerli (ranibizumab-eqrn) are approved as biosimilars to Lucentis (ranibizumab). In Canada, Byooviz is approved as a biosimilar to Lucentis; refer to the Canadian product monograph for biosimilar-specific labeled indications.</p></div>
<div class="block mst drugH1Div" id="F15241855"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ranibizumab may be confused with bevacizumab, ramucirumab</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299982"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2J2 (weak)</p></div>
<div class="block dri drugH1Div" id="F6222715"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53638443"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to use in patients who may become pregnant; confirm the patient is not pregnant prior to starting treatment. Patients who can become pregnant should use effective contraception prior to the initial dose, during treatment, and for at least 3 months after the last monthly intravitreal injection (Naderan 2021; Peracha 2016) or at least 12 months after the last the 24-week implant.</p></div>
<div class="block pri drugH1Div" id="F3025072"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor; VEGF is required to achieve and maintain normal pregnancies. Reports of intravitreal VEGF inhibitor use in pregnancy (Peracha 2016; Naderan 2021), and outcome data specific to use of ranibizumab in pregnancy are limited (Akkava 2019; Fossum 2018; Jouve 2015; Penčák 2022; Sakai 2022; Sarhianaki 2012). Based on studies in nonpregnant adults, VEGF inhibitors can alter systemic concentrations of VEGF and placental growth factor following intravitreal administration (Peracha 2016; Zehetner 2015). Until additional data are available, use during the first trimester should be avoided and use later in pregnancy should be based on patient specific risks versus benefits (Peracha 2016; Polizzi 2015).</p></div>
<div class="block brc drugH1Div" id="F20548220"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Ranibizumab can be detected in breast milk (Juncal 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Case reports have evaluated the presence of ranibizumab and VEGF-A concentrations in breast milk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Data related to the presence of ranibizumab in breast milk are available from 2 patients treated with intravitreal ranibizumab for myopic choroidal neovascularization (CNV). The first patient was 16 months postpartum and stopped breastfeeding prior to the dose; breast milk was not pumped outside of the study visits. The second patient was 1 month postpartum and continued breastfeeding during treatment. For both patients, breast milk was collected prior to and on days 1 through 7, then at intervals up to 28 days following the injection. Ranibizumab was detected in the breast milk of the patient who stopped breastfeeding on the third day after the injection (34.7 ng/mL), with concentrations increasing over time. VEGF-A concentrations decreased from 22.8 ng/mL at baseline to 12.3 ng/mL on day 1, with a further decrease to 4.9 ng/mL on day 28. The patient who continued breastfeeding regularly did not have detectable concentrations of ranibizumab in breast milk and VEGF-A concentrations did not change (Juncal 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• VEGF-A breast milk concentrations were also measured in a lactating patient, 6 months postpartum, administered 4 intravitreal injections of ranibizumab 0.5 mg for idiopathic CNV. This patient stopped breastfeeding for 3 days after each treatment but expressed breast milk to maintain lactation. VEGF-A breast milk concentrations decreased within 6 to 12 hours after each injection, then increased to pre-injection concentrations within 24 hours. Ranibizumab concentrations were not evaluated (Huang 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neither paper evaluated possible effects to a breastfed infant (Huang 2022; Juncal 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F3025120"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Intraocular pressure (prior to and 30 minutes following injection via tonometry); consider checking for perfusion of the optic nerve head immediately following injection; signs of infection/inflammation (for first week following injection); retinal perfusion, endophthalmitis; visual acuity. Perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy to inspect the implant for dislodgement prior to and after the refill-exchange procedure. Monitor implant and tissue overlying the implant routinely for signs and symptoms of conjunctival blebs, conjunctival erosion, conjunctival retraction, endophthalmitis, implant dislocation, rhegmatogenous retinal detachment, and vitreous hemorrhage.</p></div>
<div class="block pha drugH1Div" id="F3025108"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;text-align:justify;display:inline">Ranibizumab is a recombinant humanized monoclonal antibody fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.</p></div>
<div class="block phk drugH1Div" id="F3025110"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Low levels are detected in the serum following intravitreal injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Implant: ~25 weeks; vitreous: ~9 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Implant: 26 days (range: 1 to 89 days).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5378700"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ranivisio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Ranivisio | Ximluci</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Accentrix | Lucentis</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Ranivisio</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ranivisio</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Patizra</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Accentrix | Lucentis | Oceva | Ranieyes | Razumab | Visumab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Ximluci</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Ximluci</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Accentrix | Lucentis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Byooviz | Lucentis | Ranivisio</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Ximluci</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Susvimo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lucentis</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lucentis | Susvimo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31263715">
<a name="31263715"></a>Akkaya S. Early miscarriage occurring six days after intravitreal ranibizumab injection. <i>Med Hypothesis Discov Innov Ophthalmol</i>. 2019;8(2):69-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/31263715/pubmed" id="31263715" target="_blank">31263715</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Byooviz (ranibizumab) [prescribing information]. Cambridge, MA: Biogen Inc; June 2023.</div>
</li>
<li>
<div class="reference">
                  Byooviz (ranibizumab) [prescribing information]. Cambridge, MA: Biogen Inc; October 2023.</div>
</li>
<li>
<div class="reference">
                  Byooviz (ranibizumab) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Byooviz (ranibizumab) [product monograph]. Toronto, Ontario, Canada: Biogen Canada Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27256987">
<a name="27256987"></a>Chan JJT, Lam CPS, Kwok MKM, et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. <i>Sci Rep</i>. 2016;6:27082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/27256987/pubmed" id="27256987" target="_blank">27256987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32887464">
<a name="32887464"></a>Chujo S, Sugimoto M, Sasaki T, et al. Comparison of 2-year outcomes between intravitreal ranibizumab and intravitreal aflibercept for diabetic macular edema with "treat-and-extend" regimen-its usefulness and problems. <i>J Clin Med</i>. 2020;9(9):2848. doi:10.3390/jcm9092848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/32887464/pubmed" id="32887464" target="_blank">32887464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cimerli.1">
<a name="Cimerli.1"></a>Cimerli (ranibizumab) [prescribing information]. Redwood City, CA: Coherus BioSciences Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31757502">
<a name="31757502"></a>Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern®. <i>Ophthalmology</i>. 2020;127(1):P1-P65. doi:10.1016/j.ophtha.2019.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/31757502/pubmed" id="31757502" target="_blank">31757502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29350689">
<a name="29350689"></a>Fossum P, Couret C, Briend B, Weber M, Lagarce L. Safety of intravitreal injection of ranibizumab in early pregnancy: a series of three cases. <i>Eye (Lond).</i> 2018;32(4):830-832. doi:10.1038/eye.2017.305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/29350689/pubmed" id="29350689" target="_blank">29350689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15671306">
<a name="15671306"></a>Gaudreault J, Fei D, Rusit J, et al, “Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) After a Single Intravitreal Administration,” <i>Invest Ophthalmol Vis Sci</i>, 2005, 46(2):726-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/15671306/pubmed" id="15671306" target="_blank">15671306</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Heier JS, Antoszyk AN, Pavan PR, et al, “Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose Study,” <i>Ophthalmology</i>, 2006, 113(4):633-42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22672259">
<a name="22672259"></a>Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. <i>Acta Ophthalmol</i>. 2013;91(1):e74-e75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/22672259/pubmed" id="22672259" target="_blank">22672259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28412066">
<a name="28412066"></a>Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. <i>Ophthalmology</i>. 2017;124(8):1156-1164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/28412066/pubmed" id="28412066" target="_blank">28412066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35361227">
<a name="35361227"></a>Huang Y, Zhou R, Sun Z, Zheng Y, Lin B. Vascular endothelial growth factor-A level in human breast milk after intravitreal injection of ranibizumab: a case report. <i>Int Breastfeed J</i>. 2022;17(1):25. doi:10.1186/s13006-022-00463-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/35361227/pubmed" id="35361227" target="_blank">35361227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25483229">
<a name="25483229"></a>Jouve L, Akesbi J, Nordmann JP. Safety and efficacy of ranibizumab for pregnant women in idiopathic choroidal neovascularization. <i>Acta Ophthalmol</i>. 2015;93(7):597-598.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/25483229/pubmed" id="25483229" target="_blank">25483229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526521">
<a name="31526521"></a>Juncal VR, Paracha Q, Bamakrid M, et al. Ranibizumab and aflibercept levels in breast milk after intravitreal injection. <i>Ophthalmology</i>. 2020;127(2):278-280. doi:10.1016/j.ophtha.2019.08.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/31526521/pubmed" id="31526521" target="_blank">31526521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30549468">
<a name="30549468"></a>Kang HG, Choi EY, Byeon SH, et al. Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes. <i>Korean J Ophthalmol</i>. 2018;32(6):451-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/30549468/pubmed" id="30549468" target="_blank">30549468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34012972">
<a name="34012972"></a>Lai CT, Hsieh YT, Lin CJ, et al. Age, initial central retinal thickness, and OCT biomarkers have an influence on the outcome of diabetic macular edema treated with ranibizumab- tri-center 12-month treat-and-extend study. <i>Front Med (Lausanne)</i>. 2021;8:668107. doi:10.3389/fmed.2021.668107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/34012972/pubmed" id="34012972" target="_blank">34012972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19376495">
<a name="19376495"></a>Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. <i>Am J Ophthalmol</i>. 2009;148(1):43-58.e1. doi:10.1016/j.ajo.2009.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/19376495/pubmed" id="19376495" target="_blank">19376495</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lucentis (ranibizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Lucentis (ranibizumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference">
                  Lucentis (ranibizumab) [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Limited; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20980427">
<a name="20980427"></a>Massin P, Bandello F, Garweg JG, et al, “Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-Month, Randomized, Controlled, Double-Masked, Multicenter Phase II Study,” <i>Diabetes Care</i>, 2010, 33(11):2399-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/20980427/pubmed" id="20980427" target="_blank">20980427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21459215">
<a name="21459215"></a>Mitchell P, Bandello F, Schmidt-Erfurth U, et al, “The RESTORE STUDY: Ranibizumab Monotherapy or Combined With Laser versus Laser Monotherapy for Diabetic Macular Edema,” <i>Ophthalmology</i>, 2011, 118(4):615-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/21459215/pubmed" id="21459215" target="_blank">21459215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32492069">
<a name="32492069"></a>Mitchell P, Sheidow TG, Farah ME, et al; LUMINOUS study investigators. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: results from the real-world global LUMINOUS study. <i>PLoS One.</i> 2020;15(6):e0233595. doi:10.1371/journal.pone.0233595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/32492069/pubmed" id="32492069" target="_blank">32492069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33044671">
<a name="33044671"></a>Naderan M, Sabzevary M, Rezaii K, Banafshehafshan A, Hantoushzadeh S. Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective. <i>Int Ophthalmol</i>. 2021;41(2):743-751. doi:10.1007/s10792-020-01610-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/33044671/pubmed" id="33044671" target="_blank">33044671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32555630">
<a name="32555630"></a>Pearce I, Clemens A, Brent MH, et al; all the LUMINOUS™ study investigators. Real-world outcomes with ranibizumab in branch retinal vein occlusion: the prospective, global, LUMINOUS study. <i>PLoS One</i>. 2020;15(6):e0234739. doi:10.1371/journal.pone.0234739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/32555630/pubmed" id="32555630" target="_blank">32555630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35477248">
<a name="35477248"></a>Penčák M, Veith M. Intravitreal ranibizumab in pregnant patient with myopic choroidal neovascular membrane. A case report. <i>Cesk Slov Oftalmol</i>. 2022;78(2):79-83. doi:10.31348/2022/11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/35477248/pubmed" id="35477248" target="_blank">35477248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27388726">
<a name="27388726"></a>Peracha ZH, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy in pregnancy: what we know, what we don't know, and what we don't know we don't know. <i>Retina</i>. 2016;36(8):1413-1417. doi:10.1097/IAE.0000000000001200<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/27388726/pubmed" id="27388726" target="_blank">27388726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26302032">
<a name="26302032"></a>Polizzi S, Mahajan VB. Intravitreal anti-VEGF injections in pregnancy: case series and review of literature. <i>J Ocul Pharmacol Ther</i>. 2015;31(10):605-610. doi:10.1089/jop.2015.0056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/26302032/pubmed" id="26302032" target="_blank">26302032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17021318">
<a name="17021318"></a>Rosenfeld PJ, Brown DM, Heier JS, et al, “Ranibizumab for Neovascular Age-Related Macular Degeneration,” <i>N Engl J Med</i>, 2006, 355(14):1419-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/17021318/pubmed" id="17021318" target="_blank">17021318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16935211">
<a name="16935211"></a>Rosenfeld PJ, Rich RM and Lalwani, “Ranibizumab: Phase III Clinical Trial Results,” <i>Ophthalmol Clin North Am</i>, 2006, 19(3):361-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/16935211/pubmed" id="16935211" target="_blank">16935211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36438807">
<a name="36438807"></a>Sakai T, Mori C, Ohtsu F. Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System. <i>Front Pharmacol</i>. 2022;13:1063625. doi:10.3389/fphar.2022.1063625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/36438807/pubmed" id="36438807" target="_blank">36438807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22496030">
<a name="22496030"></a>Sarhianaki A, Katsimpris A, Petropoulos IK, Livieratou A, Theoulakis PE, Katsimpris JM. Intravitreal administration of ranibizumab for idiopathic choroidal neovascularization in a pregnant woman. <i>Klin Monbl Augenheilkd</i>. 2012;229(4):451-453. doi:10.1055/s-0031-1299207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/22496030/pubmed" id="22496030" target="_blank">22496030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930258">
<a name="21930258"></a>Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. <i>Am J Ophthalmol</i>. 2012;153(2):327-333.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/21930258/pubmed" id="21930258" target="_blank">21930258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29309486">
<a name="29309486"></a>Stahl A, Krohne TU, Eter N, et al. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. <i>JAMA Pediatr</i>. 2018;172(3):278-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/29309486/pubmed" id="29309486" target="_blank">29309486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31522845">
<a name="31522845"></a>Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. <i>Lancet</i>. 2019;394(10208):1551-1559.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/31522845/pubmed" id="31522845" target="_blank">31522845</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Susvimo (ranibizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31687203">
<a name="31687203"></a>Wang F, Yuan Y, Wang L, et al. One-year outcomes of 1 dose versus 3 loading doses followed by pro re nata regimen using ranibizumab for neovascular age-related macular degeneration: the ARTIS trial. <i>J Ophthalmol.</i> 2019;2019:7530458. doi:10.1155/2019/7530458<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/31687203/pubmed" id="31687203" target="_blank">31687203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24326106">
<a name="24326106"></a>Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. <i>Ophthalmology</i>. 2014;121(3):682-692.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/24326106/pubmed" id="24326106" target="_blank">24326106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467377">
<a name="27467377"></a>Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. <i>Retina</i>. 2017;37(4):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/27467377/pubmed" id="27467377" target="_blank">27467377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26024110">
<a name="26024110"></a>Zehetner C, Bechrakis NE, Stattin M, et al. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy. <i>Invest Ophthalmol Vis Sci</i>. 2015;56(5):3279-3286. doi:10.1167/iovs.15-16686<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/26024110/pubmed" id="26024110" target="_blank">26024110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27529839">
<a name="27529839"></a>Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. <i>Retina</i>. 2017;37(4):710-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ranibizumab-including-biosimilars-drug-information/abstract-text/27529839/pubmed" id="27529839" target="_blank">27529839</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10337 Version 216.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
